About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNCT00748839

Heparin-Induced Thrombocytopenia: Development and Validation of a Predictive Clinical

Although Heparin-induced thrombocytopenia (HIT) is a rare complication of heparin treatment, it results in a high rate of morbidity and mortality, the cumulative rate of thrombosis recurrence, amputat...

Lead sponsor: Centre Hospitalier Universitaire de Saint Etienne•27 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Centre Hospitalier Universitaire de Saint Etienne

Collaborators

Hyphen BioMed
CIC-EC de Saint-Etienne
Groupe d'étude sur l'Hémostase et la Thrombose
Association Française des centres régionaux de Pharmacovigilance
Laboratoires Organon
Sanofi

Purpose : To create and validate a score predicting the diagnosis of HIT

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•all patients presenting, either during or immediately after treatment:
•* thrombocytopenia and/or venous or arterial thrombosis
•* for whom a request for biological assessment to check for HIT (anti-H-PF4 ELISA test) is to be addressed to the specialized haemostasis laboratory participating in the study

Exclusion Criteria

•do not possess sufficient clinical data prior to performance of the biological test
•cannot assure follow-up of the patient until normalization of the platelet count

Related studies

COMPLETEDPhase 2

Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II

NCT00861692 · Heparin-induced Thrombocytopenia Type II

Argatroban Monitoring in Acute Suspected Heparin-induced Thrombocytopenia.

NCT06066762 · Heparin-induced Thrombocytopenia

Comparison of Pre-test Probability Model for Heparin-induced Thrombocytopenia in Post-operative Cardiac Surgery

NCT05783895 · Heparin-induced Thrombocytopenia

PLATELET Function Assay With Flow Imaging on ImageSTREAM Cytometer

NCT04842760 · Platelet Disorder, Heparin-induced Thrombocytopenia, and more

TERMINATEDPhase 3

Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban

NCT03809481 · Heparin-induced Thrombocytopenia

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 27, 2012Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment2,700

Start dateMar 2009

Last updatedNov 27, 2012

Condition

Heparin-induced Thrombocytopenia

Locations shown

ETS de Franche Conté - Laboratoire d'Immuno Hématologie

Besançon

CHU Cavale Blanche Laboratoire d'Hématologie

Brest

Laboratoire d'hématologie - Hôpital Louis Pradel

Bron

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 27, 2012Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions